

Welcome Thomas Bogenrieder*June 25, 2020*

We are very happy to welcome Thomas Bogenrieder, MD, PhD, as Chief Clinical Officer of AMAL Therapeutics as of July 1, 2020. Thomas will join AMAL's operations in Geneva, reporting into Madiha Derouazi. In this new role, he will focus on AMAL's preclinical and clinical research activities especially in the vaccine and oncolytic virus areas, to support and promote BI's Cancer Immunology and Immune Modulation unit and interface closely with BI's Oncology Medical organization to advance and integrate the concepts in the overall portfolio.



Thomas has more than 25 years of experience in academic research (molecular biology and immunology), clinical practice (dermatology, clinical immunology and immune-oncology) and clinical development in the biopharmaceutical industry. He has worked in the biopharmaceutical industry for more than 15 years, holding positions in oncology drug development and medical affairs, encompassing assignments in Germany, Europe and at a global level.

Thomas qualified in Medicine at the Albert-Ludwigs-University, Freiburg (Germany), after studying medicine in Homburg/Saar (Germany) and at Louis Pasteur University Strasbourg (France). He completed a post-doctoral fellowship in molecular cancer biology at Memorial Sloan-Kettering Cancer Center in New York and worked as a visiting scientist at the Wistar Institute in Philadelphia. Thomas also holds a PhD in "Clinicopathological and Molecular Aspects of Cutaneous Melanoma" from the University of Utrecht (The Netherlands). He is board-certified and practiced Dermatology and Clinical Immunology at the University of Regensburg and in private practice in Germany before entering the Industry.

From 2010 to 2018 Thomas was first Senior Clinical Research Physician then Group Leader Oncology with Boehringer-Ingelheim, based in Vienna, where he was responsible primarily for early oncology therapeutic programs, strategy and development. More recently, Thomas advised several biotech companies in their early stage clinical development, both as oncology advisor and Chief Medical Officer (CMO).

We warmly welcome or even welcome back Thomas to Boehringer Ingelheim and we look forward to working with him soon.

Madiha